![](https://investorshub.advfn.com/uicon/489086.png?cb=1492211412)
Thursday, January 05, 2017 4:58:57 PM
http://seekingalpha.com/article/4034630-supernus-pharmaceuticals-offers-rare-opportunity-investors
Summary
Supernus is a biotech firm with approved products..
Sales from these products are growing at an impressive rate..
The stock is underfollowed by analyst and may still be "under the radar"..
The company offers a promising pipeline with two compounds in Phase II/Phase III clinical trials.
Introduction
Supernus Pharmaceuticals (NASDAQ:SUPN) is a rarity among the thousands of publicly-traded biotechnology firms; it has approved products, revenue and earnings. While the company's sales are growing at a double digit rate, it also has promising drug candidates working their way through late-stage clinical trials. Preliminary results from these trials have been positive, and both compounds offer substantial revenue potential if approved. With a promising pipeline, strong top and bottom line growth and only a handful of analysts covering the stock, Supernus' stock may be poised to continue its market-beating performance.
Long SUPN
Recent SUPN News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/17/2024 09:15:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:15:31 PM
- Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 08:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:25:14 PM
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy • GlobeNewswire Inc. • 05/23/2024 08:05:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:09:06 PM
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures • GlobeNewswire Inc. • 05/09/2024 08:05:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:11:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:08:06 PM
- Supernus Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 08:05:50 PM
- M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America • PR Newswire (US) • 05/07/2024 02:00:00 PM
- Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story • GlobeNewswire Inc. • 05/01/2024 12:00:32 PM
- Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 • GlobeNewswire Inc. • 04/24/2024 08:05:53 PM
- Supernus Provides Regulatory Update for SPN-830 • GlobeNewswire Inc. • 04/08/2024 12:00:16 PM
- Supernus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/06/2024 09:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:01:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:00:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 10:01:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 10:00:40 PM
- Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 02/28/2024 09:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:04:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:03:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:02:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:00:51 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM